An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Condition:   Neoplasms by Site
Interventions:   Biological: Relatlimab;   Biological: BMS-936558
Sponsor:   Bristol-Myers Squibb
Recruiting - verified September 2017

http://ift.tt/2wEug7M